Review
Dani Blum’s April 13 New York Times article, F.D.A. Calls on Drug Developers to Publish Missing Data from Thousands of Trials, provides a clear and accessible summary of FDA’s recent press release1 reminding more than 2,200 sponsors and investigators of their obligations to submit clinical trial results to ClinicalTrials.gov. The article highlights the public health implications of incomplete reporting—particularly the under‑disclosure of negative or inconclusive findings—and notes potential consequences such as civil monetary penalties and loss of NIH funding eligibility.
The FDA press release references an internal analysis estimating that 29.6% of highly likely applicable clinical trials (HLACTs) have not submitted required results, implying a 70.4% compliance rate. While the press release does not go into detail on the agency’s methodology, this figure is substantially higher than compliance rates reported in external peer‑reviewed analyses. Mughal et al. (Jan 2025)2 reported 23% compliance among HLACTs from 2017–2024, and DeVito et al. (2020)3 reported 40.9% compliance for 2018–2019. Mughal et al. (Sept 2025)4 further examined the post- FDAAA 801 time-frame (2017-2024) in a sponsor‑level analysis to evaluate compliance among different sponsor categories (i.e., industry, NIH-sponsored, and academic). While the all-sponsor compliance with 12-month reporting was 37.2%, there was a 73.7% compliance rate among industry sponsors, a figure that closely aligns with FDA’s internal estimate of 70.4%.
This alignment suggests that FDA’s internal figure may largely reflect the performance of industry sponsors, who consistently demonstrate the highest compliance across studies. In contrast, Mughal et al. (Sept 2025) found slightly lower compliance among NIH sponsors (71.0%) and markedly lower compliance among academic sponsors (25.5%), with smaller‑portfolio sponsors also trending toward reduced reporting rates. Taken together, these data indicate that while FDA’s current outreach focuses on drug and device manufacturers, non‑industry sponsors—particularly academic institutions—represent a substantial portion of the remaining compliance gap and will be essential to address in any comprehensive effort to improve results reporting.
ClinicalTrials.gov continues to evolve, and the platform already offers a number of useful tools for understanding study status and regulatory obligations. As the site expands its capabilities, one potential enhancement would be the ability to filter studies based on whether a drug or device trial is FDA‑regulated. This information is already displayed on each study’s registration page and making it available as a searchable field would further support researchers and stakeholders in identifying studies subject to FDAAA 801 requirements and conducting more precise compliance assessments.
The platform also includes a search option to identify studies explicitly listed with “FDAAA 801 Violations.” Although only a small number of searchable studies currently appear in this category, the feature itself has the potential to be informative and reflects the site’s commitment to improving transparency. Increasing its visibility or integrating it more directly into common search pathways could help users take fuller advantage of this functionality, particularly those examining patterns of non‑compliance across sponsor types.
Overall, FDA’s initiative represents a constructive step toward strengthening enforcement of FDAAA 801. While some observers may view this action as symbolic, symbolic and substantive enforcement are not mutually exclusive—symbolic action often creates the conditions for substantive change. Early, highly visible actions often serve to reset expectations, signal regulatory priorities, and lay the groundwork for more comprehensive enforcement efforts. It is possible that FDA’s current apparent focus on industry sponsors reflects a phased approach, with future efforts directed toward other sponsor categories. It would be informative to gain insight on whether the 70.4% compliance rate reflects only industry sponsors or all studies that meet the HLACT criteria, and to further understand if FDA has a plan to pursue non-industry sponsors. Regardless, increased attention to results reporting is an encouraging development for clinical trial transparency and public trust.
References
Office of the Commissioner. (2026, April 13). FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results. U.S. Food and Drug Administration; FDA. https://www.fda.gov/news-events/press-announcements/fda-reminds-more-2200-sponsors-and-researchers-disclose-trial-results?utm_source=copilot.com
Mughal Z, Fu R, Luechtefeld T, Chiswell K, Kleinstreuer N, Shaw G, and Tidmarsh GF. Compliance with Results Reporting at ClinicalTrials.gov Before and After the 2017 FDAAA Final Rule: A Comparative Analysis. Journal of the Academy of Public Health. Jan 2025. https://doi.org/10.70542/rcj-japh-art-vr3aga
DeVito NJ, Bacon S, and Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet (London, England). 2020 Feb 1; 395:361–9. doi: 10.1016/S0140-6736(19)33220-9
Mughal Z, Luechtefeld T, Cashman JC, and Tidmarsh GF. Sponsor‑Level Compliance with ClinicalTrials.gov Reporting Requirements: A Comprehensive Analysis. Journal of the Academy of Public Health. Sept 2025. https://doi.org/10.70542/rcj-japh-art-1n5qt00
